As drug development shifts over time to address unmet medical needs and more targeted therapies are developed, previously unseen pharmacological or off-target effects may occur in treatment. Designed to provide practical information for the bench toxicologicpathologist working in pharmaceutical drug research, Toxicologic Pathology: Nonclinical Safety Assessment presents a histopathologic description of lesions observed during drug development and discusses their implication in the drug development process.
Divided into two sections, the book systematically assists pathologists in making a determination as to the origin and potential importance of a lesion and its relevance for assessing human risk. The first section includes eight "concept" chapters to orient pathologists in areas that are important for effective interaction with other pathologists as well as the many non-pathologists involved in drug development. The second section is made up of organ-based chapters, each including light microscopic and electron microscopicdescriptions of pathological lesions, differential diagnoses, biological consequences, pathogenesis, mechanism of lesion formation, and the expected clinical pathology correlates.
This volume presents critical information—both published and unpublished and gained through personal experience—to improve the quality of drug safety evaluation and to expedite and improve the efficiency of the process. This book is crafted to assist students, residents, and toxicologic pathologists in their early career phase by serving as a resource that can effectively be used as a ready reference next to the microscope. In addition, more experienced pathologists will find this volume to be invaluable during theirassessments. The book is also a valuable reference for toxicologists to assist in understanding compound-related pathological findings and to provide background for working on a range of toxicological problems.
- Provides practical information for the bench toxicologic pathologist working in pharmaceutical drug research and development
- Presents histopathologic descriptions of lesions noted in drug development
- Contains information related to the lesion to assist in determining its origin and potential biological significance as well as relevance while assessing human risk
- Includes material on clinical pathology, drug development, nonclinical safety, drug metabolism, and toxicogenomics
Concepts in Drug Development
Overview of Drug Development
James A. Popp and Jeffery A. Engelhardt
Nonclinical Safety Evaluation of Drugs
Thomas M. Monticello and Jeanine L. Bussiere
Toxicokinetics and Drug Disposition
David D. Christ
Introduction to Toxicologic Pathology
Judit E. Markovits, Page R. Bouchard, Christopher J. Clarke, and Donald N. McMartin
Routine and Special Techniques in Toxicologic Pathology
Daniel J. Patrick and Peter C. Mann
Principles of Clinical Pathology
Robert L. Hall
Toxicogenomics in Toxicologic Pathology
Mark J. Hoenerhoff and David E. Malarkey
Spontaneous Lesions in Control Animals Used in Toxicity Studies
Robert C. Johnson, Robert H. Spaet, and Daniel L. Potenta
Judit E. Markovits, Graham R. Betton, Donald N. McMartin, and Oliver C. Turner
Liver, Gallbladder, and Exocrine Pancreas
Russell C. Cattley, James A. Popp, and Steven L. Vonderfecht
David J. Lewis and Tom P. McKevitt
Kendall S. Frazier and John Curtis Seely
Kristin Henson, Glenn Elliott, and Gregory S. Travlos
Patrick J. Haley
Bone, Muscle, and Tooth
John L. Vahle, Joel R. Leininger, Philip H. Long, D. Greg Hall, and Heinrich Ernst
Calvert Louden and David Brott
Sundeep Chandra, Mark J. Hoenerhoff, and Richard Peterson
Reproductive System and Mammary Gland
Justin D. Vidal, Michael L. Mirsky, Karyn Colman, Katharine M. Whitney, and Dianne M. Creasy
Zbigniew W. Wojcinski, Lydia Andrews-Jones, Daher Ibrahim Aibo, and Robert Dunstan
Mark T. Butt, Robert Sills, and Alys Bradley
Special Senses: Eye and Ear
James A. Render, Kenneth A. Schafer, and Richard A. Altschuler
Pritam S. Sahota is the Executive Director of Special Projects Pathology at the Novartis Institutes for Biomedical Research in East Hanover, New Jersey, USA.
James A. Popp is with Stratoxon LLC in Lancaster, Pennsylvania, USA. Jerry F. Hardisty is with Experimental Pathology Laboratories in Sterling, Virginia.
Chirukandath Gopinath is an Independent Consultant in Toxicology/Pathology in Cambridgeshire, UK.